The reports are likely to reignite calls, particularly from Democrats, to pass substantial drug pricing reforms. In a Dear Colleague letter accompanying the report, Oversight Chairman Carolyn Maloney (D-N.Y.) emphasized the need to pass H.R. 3, House Democrats’ signature drug pricing bill, which would let Medicare negotiate directly with drug companies over the prices of their products.
“My hope is that these hearings and staff reports will shed additional light on this problem and spur the President and the Senate to finally act on H.R. 3,” Maloney wrote.